Solid state NMR and bioequivalence comparison of the pharmacokinetic parameters of two formulations of clindamycin
KAUST DepartmentAdvanced Nanofabrication, Imaging and Characterization Core Lab
Analytical Chemistry Core Lab
Analytical Core Lab
Imaging and Characterization Core Lab
Online Publication Date2011-07-07
Print Publication Date2011-07-01
Permanent link to this recordhttp://hdl.handle.net/10754/561656
MetadataShow full item record
AbstractObjective: The purpose of this study was to compare the pharmacokinetic parameters and determine the bioequivalence of a generic formulation of clindamycin that is sold in the local markets in the Middle East (Clindox® 150 mg capsule; test) with a reference formulation (Dalacin C® 150 mg capsule) in healthy adult male volunteers. Methods: A single-dose, open-label, 2-period crossover study was conducted. Healthy male volunteers were randomly assigned to oral administration of a single treatment of the reference and test formulations. The same groups were given the alternate formulation. After dosing, serial blood samples were withdrawn for a period of 24 h. Serum harvested from the blood samples was analyzed for clindamycin by high performance liquid chromatography (HPLC) with ultraviolet detection. Pharmacokinetic parameters, including AUC0-∞, AUC 0-t, Cmax, Ke, tmax and t 1/2 were determined from the serum concentrations for both formulations (test and reference). The products were tested for bioequivalence after log-transformation of the data. Results: 24 healthy adult male volunteers from Jordan (mean [SD] age, 28.8 (7.7) years (range 19-45 years); height, 175.8 (10.6) cm (range 159.0-192.0 cm); weight, 75.6 (11.0) kg (range 58-101 kg); and body mass index, 24.4 (1.8) kg/m2 (range 21.3-28 kg/m2)) were enrolled in and completed the study. The 13C NMR spectra for both Dalacin C® and Clindox® showed 18 distinct lines associated with the 18 different carbon atoms. Conclusion: The statistical comparison suggested that Clindox® capsules are bioequivalent to Dalacin C® capsules. The 13C CPMAS results confirmed that the two drugs exhibit typical clindamycin spectra. ©2011 Dustri-Verlag Dr. K. Feistle.
PublisherDustri-Verlgag Dr. Karl Feistle
- Pharmacokinetic properties and bioequivalence of two compound formulations of 1500 mg ampicillin (1167 mg)/probenecid (333 mg): a randomized-sequence, single-dose, open-label, two-period crossover study in healthy Chinese male volunteers.
- Authors: Wu H, Liu M, Wang S, Feng W, Yao W, Zhao H, Wei M
- Issue date: 2010 Mar
- Pharmacokinetics and bioequivalence study of clindamycin hydrochloride formulations after single-dose administration in healthy Chinese male volunteers.
- Authors: Li J, Wang N, Zhang ZJ, Tian Y, Tang W, Chen Y
- Issue date: 2008
- Bioequivalence and pharmacokinetic comparison of two mycophenolate mofetil formulations in healthy Chinese male volunteers: an open-label, randomized-sequence, single-dose, two-way crossover study.
- Authors: Zhang Q, Tao Y, Zhu Y, Zhu D
- Issue date: 2010 Jan
- Relative bioavailability and pharmacokinetic properties of two different enteric formulations of esomeprazole in healthy Bangladeshi male volunteers: An open-label, single-dose, randomized-sequence, two-way crossover study.
- Authors: Ullah MA, Shams-Ud-Dowla, Maruf AA, Azad MA, Shohag MH, Sultana R, Latif AH, Hasnat A
- Issue date: 2010 Jul
- Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
- Authors: Alkhalidi BA, Tamimi JJ, Salem II, Ibrahim H, Sallam AA
- Issue date: 2008 Oct